For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Thymosin beta-4
Illustration for Thymosin beta-4

THE PEPSRADAR ENCYCLOPEDIA

Thymosin beta-4

Tissue biology and ophthalmic research

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Corrected October 11, 2026: We removed upcoming-trial records that turned out not to be real studies (fake ClinicalTrials.gov registrations). Corrections log

Thymosin beta-4 · KEY FACTS

Content updated · how dates work

Saved peptides

Compare: Thymosin alpha-1 vs Thymosin beta-4

What is Thymosin beta-4?

Thymosin beta-4 is a full-length 43-residue peptide studied in tissue biology. The selected human study tested an ophthalmic preparation for dry eye, with negative primary endpoints.

Biological role or research focus

Tissue biology and ophthalmic research.

Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use.

Role reference: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

Names you may encounter

Tβ4 · RGN-259

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Full-length 43-residue actin-binding peptide
Research focus
Tissue biology and ophthalmic research
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

Quick answers

Is Thymosin beta-4 FDA approved?
No. No FDA-approved drug contains Thymosin beta-4. Source ↗
Is Thymosin beta-4 safe?
Investigational protein, not FDA-approved. Small trials of eye drops and infusions reported mostly mild side effects, but long-term and whole-body safety remain unknown. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is Thymosin beta-4 banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.3 Growth factors and growth factor modulators). Source ↗
Has the FDA taken action over Thymosin beta-4?
Yes. Our records list 2 FDA actions naming it, most recently on January 20, 2026: FDA warning letter to an outsourcing facility (GenoGenix) naming Thymosin Beta-4 as an unapproved new drug and an unlicensed biological product. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research
StudyTypePopulation / model
RGN-259 dry-eye phase 2 study (2015)Human randomized trial72 people with moderate to severe dry eye.
RGN-259 · small severe dry-eye trialHuman phase 2 randomized trialNine patients with severe dry eye; the abstract reports outcomes for 12 treated eyes and six control eyes.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2015

RGN-259 dry-eye phase 2 study

Did ophthalmic treatment meet the primary dry-eye endpoints?

Population / model
72 people with moderate to severe dry eye.
Study design
Randomized double-masked placebo-controlled phase 2 ophthalmic study over 28 days.
Main finding
Neither primary endpoint—ocular discomfort nor inferior corneal staining at day 29—showed a statistically significant treatment benefit. Some secondary outcomes favored treatment.
Limits & context
Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use.

Source: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

Human phase 2 randomized trial · undefined

RGN-259 · small severe dry-eye trial

What did a small ophthalmic experiment report?

Population / model
Nine patients with severe dry eye; the abstract reports outcomes for 12 treated eyes and six control eyes.
Study design
Two-site double-masked vehicle-controlled trial: 28 days of eye drops and another 28 days of follow-up.
Main finding
At day 56, the reported reductions relative to vehicle were 35.1% for ocular discomfort and 59.1% for total corneal fluorescein staining. Treatment was described as well tolerated.
How to read it
Eyes and patients are different units; 18 eyes do not mean 18 independent participants.
Limits & context
Very small sample and multiple assessment times limit confidence. Read beside the larger 72-person trial, which missed its primary endpoints. Ophthalmic findings do not establish systemic injury recovery or equivalence to TB-500 fragments.

Source: RGN-259 · small severe dry-eye trial · undefined ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

18 registered studies name Thymosin beta-4 as an intervention; 0 are recruiting or under way, 1 has not started recruiting yet, 12 completed and 5 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589 · ReGenTree, LLC
CompletedPhase 32023-04-1170
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
NCT02974907 · ReGenTree, LLC
CompletedPhase 32016-11601
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
NCT03937882 · ReGenTree, LLC
CompletedPhase 32019-05-24700
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
NCT07586865 · Beijing Northland Biotech. Co., Ltd.
Not yet recruitingPhase 22026-05-18189
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
NCT05984134 · Beijing Northland Biotech. Co., Ltd.
CompletedPhase 22022-07-1590
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
NCT02600429 · ReGenTree, LLC
TerminatedPhase 32015-09-1718
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction
NCT05485818 · Beijing Northland Biotech. Co., Ltd.
CompletedPhase 22020-11-2362
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
NCT01311518 · RegeneRx Biopharmaceuticals, Inc.
WithdrawnPhase 22019-070

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 18 listed studies.

Search additional PubMed records ↗

Risks & interactions

Investigational protein, not FDA-approved. Small trials of eye drops and infusions reported mostly mild side effects, but long-term and whole-body safety remain unknown.

Human safety data: Trials only

Phase 1 infusion studies in healthy volunteers reported no serious adverse events, and eye-drop trials reported few or none. These were small and short, and no long-term whole-body safety data were found.

Warning signs in animal or lab studies: Cancer, now or in the past

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Harms seen in animal or lab studies

  • In tumor and lab studies, higher thymosin beta-4 levels have been linked to tumor spread and blood-vessel growth

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Intravenous thymosin beta4 in healthy volunteers: phase 1 (2010) ↗ · First-in-human phase 1 study of recombinant thymosin beta4 (2021) ↗ · Thymosin beta 4 ophthalmic solution for dry eye: phase 2 (2015) ↗ · RGN-259 in neurotrophic keratopathy: phase 3 (2022) ↗ · Thymosin beta4: a potential molecular target for tumor therapy (review) ↗

What the featured evidence can tell us

No adverse events were reported in this small short study, which cannot exclude uncommon harms or establish safety across other routes.

Source: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

Identity, route, and evidence limits

Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use.

Source: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Full-length thymosin beta-4 was not found on FDA's 503A category lists. Its fragment TB-500 was in category 2 until the nomination was withdrawn (April 2026). source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.3 Growth factors and growth factor modulators
Named explicitly ("Thymosin-beta4 and its derivatives"). source

FDA actions

  • FDA warning letter to an outsourcing facility (GenoGenix) naming Thymosin Beta-4 as an unapproved new drug and an unlicensed biological product. (2026-01-20) source
  • FDA warning letter (Warrior Labz) citing TB-500 products described as thymosin beta-4 sold online as unapproved new drugs. (2023-06-12) source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical context & research status

The featured study concerns eye drops for moderate to severe dry eye. It does not establish a systemic injury-recovery use or validate material sold as TB-500.

Source: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

How Thymosin beta-4 works

Thymosin beta-4 is associated with actin binding and tissue responses. This biological role motivates research but does not establish a clinical tissue-repair treatment.

Source: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

Molecular structure

Thymosin beta-4: 2d molecular structure. Full-length acetylated thymosin beta-4 is shown, not the seven-residue fragment illustrated on the TB-500 page.⤢ Enlarge 2D
2D molecular structureFull-length acetylated thymosin beta-4 is shown, not the seven-residue fragment illustrated on the TB-500 page.PubChem · CID 45382195 ↗

Questions worth asking

  • Is thymosin beta-4 the same as TB-500?
  • What population, comparator, and route were actually studied?
  • Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Is thymosin beta-4 the same as TB-500?

This site distinguishes full-length thymosin beta-4 from the acetylated seven-residue TB-500 fragment shown in its separate profile. Vendor naming alone cannot establish identity.

Source: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

Does this page establish a supplier’s product quality?

No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.

Source: Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. · 2015 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

RESEARCH FIELD GUIDE

Where research peptides come from, and why the batch matters more than the brand

Dozens of online shops sell research peptides, and many look like different companies selling the same products. We compared 15 shops' menus, prices and 98 of their lab reports. The pattern fits a market where many brands buy finished vials from a few manufacturers and sell them under their own labels. So the question to ask isn't "which brand?" but "was the lot I'm buying tested, and does the lab confirm it?"

Read the guide →

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Thymosin beta-4

Download illustration ↓Source record ↗
Thymosin beta-4 2d molecular structure

Full-length acetylated thymosin beta-4 is shown, not the seven-residue fragment illustrated on the TB-500 page.